Menu
这是描述信息
通用分类

幽门螺杆菌感染与冠心病发病的相关性研究

2020-07-09

概要:

摘要:目的  探讨幽门螺杆菌感染(Hp)与冠心病发病的相关性,为研究冠心病的发病机制提供理论依据。方法选取医院2010年12月-2012年12月收治的冠心病患者75例为冠心病组,并选择同期进行体检的健康者75名作为对照为非冠心病组,应用酶联免疫吸附法(ELISA)检测血清中Hp抗体和冠心病组中内皮素-1和高敏C-反应蛋白(hs-CRP)的指标,对冠心病组中Hp感染与非Hp感染患者之间的差异进行比较;采用SPSS 13.0软件进行数据分析。结果  在冠心病组中Hp抗体阳性率为61.33%,显著高于非冠心病组的29.33%,两组比较,差异有统计学意义(P <0.05);在冠心病组患者中Hp感染血浆内皮素及hs-CRP水平分别为(61.09±35.81)pg/ml和(10.35±2.91)mg/L,显著高于非Hp感染患者的(40.21±16.73)pg/ml和(7.21±2.15)mg/L,两组相比差异有统计学意义(P <0.05)。结论  Hp感染与冠心病发病呈显著相关性,Hp感染血浆内皮素和hs-CRP水平显著升高,可能是其导致冠心病的发病机制之一。

 

Abstract: OBJECTIVE To explore the correlation between the Helicobacter pylori infections and the coronary heart disease so as to provide theoretical basis for study of pathogenesis of the coronary heart disease. METHODS A total of 75patients with coronary heart disease who were treated in the hospital from Dec 2010to Dec 2012were chosen as the coronary heart disease group, meanwhile, 75healthy people who underwent physical examination were set as the non-coronary heart disease group, then the serum H. pylori antibodies and endothelin-1and high-sensitivity C-reactive protein (hs-CRP) were detected with the use of enzyme-linked immunosorbent assay (ELISA), and the statistical analysis of data was performed by using SPSS13.0 software. RESULTS The positive rate of H. pylori antibodies was 61.33%in the coronary heart disease group, significantly higher than 29.33%in the non-coronary heart disease group (P <0.05). In the coronary heart disease group, the plasma endothelin level of the patients with H. pylori infection was (61.09±35.81) pg/mL, significantly higher than (40.21±16.73) pg/mL of the patients without H. pylori infection; the hs-RP level of the patients with H. pylori infection was (10.35±2.91) mg/L, significantly higher than (7.21±2.15) mg/L of the patients without H. pylori infection (P <0.05). CONCLUSIONT he H. pylori infection is significantly correlated with the coronary heart disease; the elevated levels of plasma endothelin and hs-CRP may be one of the mechanisms of pathogenesis of coronary heart disease.

这是描述信息
这是描述信息

扫描二维码
关注华亘控股微信公众号

ICP经营许可证编号:京ICP备14021677号 北京华亘安邦科技有限公司   Design by CE ULITAME